continued use of osimertinib reduces cns metastasis in egfr mutant lung cancer
Published 8 months ago • 623 plays • Length 2:06Download video MP4
Download video MP3
Similar videos
-
0:55
osimertinib for egfr-mutant lung cancer
-
2:33
adaura: osimertinib adjuvant therapy in egfr mutated nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:18:11
management of egfr-mutant lung cancer with central nervous system metastases
-
3:30
adaura: osimertinib adjuvant therapy on cns disease recurrence
-
3:02
osimertinib for treating non-small cell lung cancer
-
0:48
investigating osimertinib for brain activity in egfr-mutated lung cancer
-
1:44
osimertinib and chemotherapy in egfr lung cancer with tp53 and rb1 alterations
-
2:23
therapeutic strategies for egfr-mutated lung cancer
-
3:13
osimertinib responses after rociletinib treatment of t790m-positive nsclc
-
3:38
overview of the world of egfr mutant lung cancers
-
3:34
repeat biopsy in lung cancer patients with egfr mutation
-
0:42
dr. fidler discusses osimertinib in egfr-mutated lung cancer
-
9:25
volumetric response of brain metastases in egfr mutant nsclc | lisa ni, md
-
3:13
updates from adaura: continued dfs benefit with osimertinib vs. placebo
-
3:02
osimertinib in advanced egfr t790m-mutant nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
3:09
case 2: osimertinib in egfr-mutated lung cancer
-
2:11
dr. low on osimertinib versus dacomitinib in egfr-mutant nsclc